Study of NXT007 vs emicizumab for hemophilia A
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe or moderate hemophilia A (with or without inhibitors), or mild hemophilia A with chronic inhibitors that lower your factor VIII levels.
- You have records of your past bleeding episodes and treatments for at least 6 months.
- If you currently use on-demand treatment, you agree to switch to a preventive treatment (emicizumab or NXT007).
- You do not have a known allergy to study drugs or their ingredients.
- You are not using certain immune-suppressing medications, like interferon or rituximab.
- You have no history of serious heart rhythm problems or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial compares two low-dose prophylactic treatments for severe hemophilia A. Patients receive either low-dose emicizumab or low-dose factor VIII to see which works better for preventing bleeding episodes.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This trial tests emicizumab, a medicine given under the skin, to see how it works in children with hemophilia A. It aims to help control bleeding, no matter if they have inhibitors or not.
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.